High Remission Rates in AML Patients with ICT01 Combo at ASCO 2025

ImCheck Therapeutics, a cutting-edge biotech firm committed to developing novel immunotherapeutic antibodies, has made notable strides in the field of acute myeloid leukemia (AML) treatment. The company recently shared its groundbreaking results during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the potential of ICT01 combination therapy which has been making waves in the biotech sector.

The ongoing EVICTION study, a comprehensive Phase I/II trial, illuminates a new horizon in AML treatment. This trial focuses on pioneering ICT01, a γ9δ2 T-cell activator, in conjunction with azacitidine and venetoclax (Aza-Ven), a treatment protocol specifically tailored for newly diagnosed AML patients unable to undergo intensive chemotherapy.

The study’s updated results are nothing short of remarkable, with a composite complete remission (CRc) rate of 96%. Of these patients, a significant 74% achieved complete remissions (CR) across multiple molecular subtypes. The potency of this innovative triple combination therapy is underscored by the high response rates observed in patients with adverse- or intermediate-risk mutations, populations traditionally less responsive to Aza-Ven.

Moreover, a promising preliminary 9-month overall survival rate of 83% was reported in patients treated with 10 mg of ICT01. This encouraging data signifies the substantial clinical potential of ICT01 as a game-changer in the combat against AML.

Dr. Stephan Braun, the Chief Medical Officer of ImCheck Therapeutics, expressed that the updated data underscores the potential of ICT01 to enhance the therapeutic effects of Aza-Ven in AML through the unique biology of γ9δ2 T cells. Dr. Braun further emphasized that the consistency and depth of responses observed with ICT01, coupled with its manageable safety profile, provide a robust foundation as they advance toward a randomized study.

ImCheck’s CEO, Pierre d’Epenoux, added that the results suggest ICT01’s ability to engage γ9δ2 T cells could offer a formidable new option for patients who are typically underserved by current therapies. Backed by this persuasive validation of their innovative approach, the company is set to accelerate the clinical development of ICT01 in treating AML, myelodysplastic syndrome, and select solid tumor indications.

In the broader biotech backdrop, this development by ImCheck Therapeutics represents a leap forward in the AML treatment paradigm. By harnessing the power of γ9δ2 T cells, the company’s innovative approach has the potential to transform treatments across oncology, autoimmune, and infectious diseases, establishing a new era in patient care.

The ICT01 clinical-stage program has demonstrated a unique mechanism of action that modulates both innate and adaptive immunity. This “first-in-class” activating antibody may deliver superior clinical outcomes compared to first-generation immunotherapy approaches. The findings from the EVICTION study offer a tantalizing glimpse of the future of AML treatment, showcasing the potential that lies within ImCheck’s pipeline compounds, as they progress toward clinical development for autoimmune and infectious diseases.